nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Bronchospasm—Teniposide—lymphatic system cancer	0.00984	0.00984	CcSEcCtD
Doxylamine—Pancytopenia—Teniposide—lymphatic system cancer	0.0095	0.0095	CcSEcCtD
Doxylamine—Dehydration—Fludarabine—lymphatic system cancer	0.00946	0.00946	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00916	0.00916	CcSEcCtD
Doxylamine—Loss of libido—Methotrexate—lymphatic system cancer	0.009	0.009	CcSEcCtD
Doxylamine—Sweating increased—Fludarabine—lymphatic system cancer	0.00856	0.00856	CcSEcCtD
Doxylamine—Sweating—Teniposide—lymphatic system cancer	0.00855	0.00855	CcSEcCtD
Doxylamine—Vertigo—Mechlorethamine—lymphatic system cancer	0.00849	0.00849	CcSEcCtD
Doxylamine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00846	0.00846	CcSEcCtD
Doxylamine—Pancytopenia—Fludarabine—lymphatic system cancer	0.00835	0.00835	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00777	0.00777	CcSEcCtD
Doxylamine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00772	0.00772	CcSEcCtD
Doxylamine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00755	0.00755	CcSEcCtD
Doxylamine—Flushing—Teniposide—lymphatic system cancer	0.00743	0.00743	CcSEcCtD
Doxylamine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00735	0.00735	CcSEcCtD
Doxylamine—Polyuria—Vincristine—lymphatic system cancer	0.00708	0.00708	CcSEcCtD
Doxylamine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00671	0.00671	CcSEcCtD
Doxylamine—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00665	0.00665	CcSEcCtD
Doxylamine—Diplopia—Carmustine—lymphatic system cancer	0.00651	0.00651	CcSEcCtD
Doxylamine—Agitation—Teniposide—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Doxylamine—Bronchospasm—Bleomycin—lymphatic system cancer	0.00634	0.00634	CcSEcCtD
Doxylamine—Leukopenia—Teniposide—lymphatic system cancer	0.00624	0.00624	CcSEcCtD
Doxylamine—Pancytopenia—Bleomycin—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Doxylamine—Liver disorder—Methotrexate—lymphatic system cancer	0.00609	0.00609	CcSEcCtD
Doxylamine—Urinary retention—Vincristine—lymphatic system cancer	0.00591	0.00591	CcSEcCtD
Doxylamine—Dehydration—Vincristine—lymphatic system cancer	0.00578	0.00578	CcSEcCtD
Doxylamine—Confusional state—Teniposide—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Doxylamine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Doxylamine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Doxylamine—Agitation—Fludarabine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Doxylamine—Dehydration—Mitoxantrone—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Doxylamine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00557	0.00557	CcSEcCtD
Doxylamine—Tachycardia—Teniposide—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Doxylamine—Malaise—Fludarabine—lymphatic system cancer	0.00552	0.00552	CcSEcCtD
Doxylamine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Doxylamine—Leukopenia—Fludarabine—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Doxylamine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00546	0.00546	CcSEcCtD
Doxylamine—Anorexia—Teniposide—lymphatic system cancer	0.00542	0.00542	CcSEcCtD
Doxylamine—Pancytopenia—Carmustine—lymphatic system cancer	0.00534	0.00534	CcSEcCtD
Doxylamine—Hypotension—Teniposide—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Doxylamine—Convulsion—Fludarabine—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Doxylamine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Doxylamine—Discomfort—Fludarabine—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Doxylamine—Pancytopenia—Vincristine—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Doxylamine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Doxylamine—Dyspnoea—Teniposide—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Doxylamine—Confusional state—Fludarabine—lymphatic system cancer	0.00504	0.00504	CcSEcCtD
Doxylamine—Depression—Carmustine—lymphatic system cancer	0.005	0.005	CcSEcCtD
Doxylamine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.005	0.005	CcSEcCtD
Doxylamine—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00497	0.00497	CcSEcCtD
Doxylamine—Decreased appetite—Teniposide—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Doxylamine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00491	0.00491	CcSEcCtD
Doxylamine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Doxylamine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Doxylamine—Rash—Mechlorethamine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Doxylamine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Doxylamine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Doxylamine—Flushing—Bleomycin—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Doxylamine—Depression—Vincristine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Doxylamine—Anorexia—Fludarabine—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Doxylamine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Doxylamine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Doxylamine—Bone disorder—Methotrexate—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Doxylamine—Sweating—Vincristine—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Doxylamine—Nausea—Mechlorethamine—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Doxylamine—Urticaria—Teniposide—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Doxylamine—Erythema—Bleomycin—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Doxylamine—Hallucination—Carmustine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Doxylamine—Sweating—Mitoxantrone—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Doxylamine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Doxylamine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Doxylamine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Doxylamine—Fatigue—Fludarabine—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Doxylamine—Hallucination—Vincristine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Doxylamine—Constipation—Fludarabine—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Doxylamine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Doxylamine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Doxylamine—Urethral disorder—Vincristine—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Doxylamine—Eye disorder—Carmustine—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Doxylamine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Doxylamine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Doxylamine—Flushing—Carmustine—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Doxylamine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Doxylamine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Doxylamine—Asthenia—Teniposide—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Doxylamine—Malaise—Bleomycin—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Doxylamine—Pruritus—Teniposide—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Doxylamine—Leukopenia—Bleomycin—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Doxylamine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Doxylamine—Erythema—Carmustine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Doxylamine—Diarrhoea—Teniposide—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Doxylamine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Doxylamine—Discomfort—Bleomycin—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Doxylamine—Confusional state—Bleomycin—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Doxylamine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Doxylamine—Tremor—Carmustine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Doxylamine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Doxylamine—Erythema—Mitoxantrone—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Doxylamine—Vomiting—Teniposide—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Doxylamine—Agitation—Carmustine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Doxylamine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Doxylamine—Asthenia—Fludarabine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Doxylamine—Rash—Teniposide—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Doxylamine—Dermatitis—Teniposide—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Doxylamine—Pruritus—Fludarabine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Doxylamine—Leukopenia—Carmustine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Doxylamine—Anorexia—Bleomycin—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Doxylamine—Agitation—Vincristine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Doxylamine—Polyuria—Methotrexate—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Doxylamine—Hypotension—Bleomycin—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Doxylamine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Doxylamine—Convulsion—Carmustine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Doxylamine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Doxylamine—Nausea—Teniposide—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Doxylamine—Vertigo—Vincristine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Doxylamine—Leukopenia—Vincristine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Doxylamine—Anxiety—Carmustine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Doxylamine—Malaise—Mitoxantrone—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Doxylamine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Doxylamine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Doxylamine—Convulsion—Vincristine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Doxylamine—Confusional state—Carmustine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Doxylamine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Doxylamine—Vomiting—Fludarabine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Doxylamine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Doxylamine—Rash—Fludarabine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Doxylamine—Dermatitis—Fludarabine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Doxylamine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Doxylamine—Tachycardia—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Doxylamine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Doxylamine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Doxylamine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Doxylamine—Anorexia—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Doxylamine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Doxylamine—Confusional state—Mitoxantrone—lymphatic system cancer	0.003	0.003	CcSEcCtD
Doxylamine—Nervous system disorder—Vincristine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Doxylamine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Doxylamine—Hypotension—Carmustine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Doxylamine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Doxylamine—Nausea—Fludarabine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Doxylamine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Doxylamine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Doxylamine—Urticaria—Bleomycin—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Doxylamine—Anorexia—Vincristine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Doxylamine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Doxylamine—Insomnia—Carmustine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Doxylamine—Irritability—Methotrexate—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Doxylamine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Doxylamine—Mood swings—Methotrexate—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Doxylamine—Hypotension—Vincristine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Doxylamine—Dyspnoea—Carmustine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Doxylamine—Somnolence—Carmustine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Doxylamine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Doxylamine—Decreased appetite—Carmustine—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Doxylamine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Doxylamine—Insomnia—Vincristine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Doxylamine—Constipation—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Doxylamine—Breast disorder—Methotrexate—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Doxylamine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Doxylamine—Decreased appetite—Vincristine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Doxylamine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Doxylamine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Doxylamine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Doxylamine—Fatigue—Vincristine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Doxylamine—Asthenia—Bleomycin—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Doxylamine—Constipation—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Doxylamine—Pruritus—Bleomycin—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Doxylamine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Doxylamine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Doxylamine—Pancreatitis—Methotrexate—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Doxylamine—Constipation—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Doxylamine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Doxylamine—Pancytopenia—Methotrexate—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Doxylamine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Doxylamine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Doxylamine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Doxylamine—Vomiting—Bleomycin—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Doxylamine—Drowsiness—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Doxylamine—Depression—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Doxylamine—Rash—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Doxylamine—Dermatitis—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Doxylamine—Asthenia—Carmustine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Doxylamine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Doxylamine—Sweating—Methotrexate—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Doxylamine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Doxylamine—Asthenia—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Doxylamine—Diarrhoea—Carmustine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Doxylamine—Nausea—Bleomycin—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Doxylamine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Doxylamine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Doxylamine—Dizziness—Carmustine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Doxylamine—Diarrhoea—Vincristine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Doxylamine—Hepatitis—Methotrexate—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Doxylamine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Doxylamine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Doxylamine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Doxylamine—Vomiting—Carmustine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Doxylamine—Dizziness—Vincristine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Doxylamine—Rash—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Doxylamine—Dermatitis—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Doxylamine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Doxylamine—Eye disorder—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Doxylamine—Vomiting—Vincristine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Doxylamine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Doxylamine—Rash—Vincristine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Doxylamine—Dermatitis—Vincristine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Doxylamine—Nausea—Carmustine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Doxylamine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Doxylamine—Immune system disorder—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Doxylamine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Doxylamine—Rash—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Doxylamine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Doxylamine—Erythema—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Doxylamine—Nausea—Vincristine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Doxylamine—Nausea—Mitoxantrone—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Doxylamine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Doxylamine—Malaise—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Doxylamine—Vertigo—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Doxylamine—Leukopenia—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Doxylamine—Convulsion—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Doxylamine—Discomfort—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Doxylamine—Confusional state—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Doxylamine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Doxylamine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Doxylamine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Doxylamine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Doxylamine—Anorexia—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Doxylamine—Hypotension—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Doxylamine—Insomnia—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Doxylamine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Doxylamine—Somnolence—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Doxylamine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Doxylamine—Fatigue—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Doxylamine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Doxylamine—Urticaria—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Doxylamine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Doxylamine—Asthenia—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Doxylamine—Pruritus—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Doxylamine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Doxylamine—Dizziness—Methotrexate—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Doxylamine—Vomiting—Methotrexate—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Doxylamine—Rash—Methotrexate—lymphatic system cancer	0.000934	0.000934	CcSEcCtD
Doxylamine—Dermatitis—Methotrexate—lymphatic system cancer	0.000933	0.000933	CcSEcCtD
Doxylamine—Nausea—Methotrexate—lymphatic system cancer	0.00088	0.00088	CcSEcCtD
